BR112022005420A2 - Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina - Google Patents

Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina

Info

Publication number
BR112022005420A2
BR112022005420A2 BR112022005420A BR112022005420A BR112022005420A2 BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2 BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2
Authority
BR
Brazil
Prior art keywords
chlorobenzyl
triazol
piperidin
methyl
morpholino
Prior art date
Application number
BR112022005420A
Other languages
English (en)
Inventor
Grzegorz Witkowski
Magdalena Tyszkiewicz
Marcin Zakrzewski
Marta Magdycz
Stanislaw Pikul
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of BR112022005420A2 publication Critical patent/BR112022005420A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. a presente invenção refere-se a um processo para a síntese de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina em duas formas cristalinas hidratadas e em uma forma cristalina anidrosa. a presente invenção também refere-se a (z)-4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)-n-cianopiperidina-1-carbimidotioato de metila que é um intermediário neste processo.
BR112022005420A 2019-09-25 2020-09-25 Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina BR112022005420A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905494P 2019-09-25 2019-09-25
PL43126919 2019-09-25
PCT/IB2020/058984 WO2021059220A1 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine

Publications (1)

Publication Number Publication Date
BR112022005420A2 true BR112022005420A2 (pt) 2022-06-21

Family

ID=73139065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005420A BR112022005420A2 (pt) 2019-09-25 2020-09-25 Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina

Country Status (13)

Country Link
US (2) US11746107B2 (pt)
EP (1) EP4041726A1 (pt)
JP (1) JP2022549863A (pt)
KR (1) KR20220069008A (pt)
CN (1) CN114466845A (pt)
AU (1) AU2020356534A1 (pt)
BR (1) BR112022005420A2 (pt)
CA (1) CA3155177A1 (pt)
IL (1) IL291569A (pt)
MX (1) MX2022002881A (pt)
TW (1) TWI769532B (pt)
WO (1) WO2021059220A1 (pt)
ZA (1) ZA202204542B (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
DE60126785T2 (de) * 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
KR101666293B1 (ko) * 2012-05-30 2016-10-13 에프. 호프만-라 로슈 아게 Pde10 억제제로서 트라이아졸로 화합물
SG11201605757SA (en) * 2013-12-20 2016-08-30 Inst Drug Discovery Substituted amino triazoles, and methods using same
PL415073A1 (pl) 2014-12-19 2016-06-20 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
PL415078A1 (pl) * 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
BR112022000576A2 (pt) 2019-07-15 2022-05-10 Oncoarendi Therapeutics Sa Aminotriazóis substituídos úteis como inibidores de quitinase

Also Published As

Publication number Publication date
EP4041726A1 (en) 2022-08-17
CN114466845A (zh) 2022-05-10
TWI769532B (zh) 2022-07-01
MX2022002881A (es) 2022-06-08
WO2021059220A1 (en) 2021-04-01
US20240025889A1 (en) 2024-01-25
KR20220069008A (ko) 2022-05-26
AU2020356534A1 (en) 2022-05-19
CA3155177A1 (en) 2021-04-01
TW202126644A (zh) 2021-07-16
JP2022549863A (ja) 2022-11-29
IL291569A (en) 2022-05-01
US20210147401A1 (en) 2021-05-20
ZA202204542B (en) 2023-01-25
US11746107B2 (en) 2023-09-05
TW202237594A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CY1118475T1 (el) Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CY1116333T1 (el) Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr
CO7170165A2 (es) Fabricación de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético
PE20171738A1 (es) Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
UY38084A (es) Oxadiazoles fungicidas
UA106220C2 (ru) Полиморфные формы гидрохлоридной соли 3-(1-{3-[5-(1-метилпиперидин-4-илметокси)-пиримидин-2-ил]-бензил}-оксо-1,6-дигидропиридазин-3-ил)-бензонитрила и способ их получения (варианты)
TN2015000521A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
BR112013004624A2 (pt) "derivados de furopiridina"
CY1124381T1 (el) Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης
BR112014032229A2 (pt) método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma
UY36574A (es) Inhibidores de bromodominios
NZ595823A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
ECSP21067828A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada
BR112021020508A2 (pt) Inibidor de jak de 7h-pirrolo[2,3-d]pirimidina
IL253601B (en) (2-5-(r4,s (5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as a neprilysin inhibitor
CY1122506T1 (el) Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη
BR112022005420A2 (pt) Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
CR20160165A (es) Acetato de 4-{4-[(1 e)-4-(2,9- diazaespiro [5.5] undec-2-il) but-1 -en-i -il]-2- metilbencil}-5-(propan-2-il) -1h-pirazol-3-ilo beta-d- glucopiranósido
PH12017500123B1 (en) Crystal of azole benzene derivative
TWI849432B (zh) 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法
PH12017500492A1 (en) Crystalline bace inhibitors
BR112022003171A2 (pt) Processo para a síntese de compostos de pirazolidinona